A preclinical report showed that addition of EMP did not enhance the efficacy of DTX [7], while other preclinical studies confirmed that EMP in combination with DTX exerted beneficial effects in prostate cancer [8,9]. The gene discussed is MAEA; the disease is prostate carcinoma.